BK | Jotup

Memo Therapeutics increases Series C financing to CHF 45 million

Retrieved on:

화요일, 5월 7, 2024

FDA, Phase, Cancer, Venture round, BK, Kidney, Risk, MTX, BK virus, Viremia, Memo, Disease, Patient, Kidney transplantation, BKV, CHF, Infection, Therapy, Viral, Pharmaceutical industry

Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.

Key Points:

Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
Erik van den Berg, CEO of Memo Therapeutics, commented: “This financing provides further external endorsement of the potential of our highly potent anti-BK virus mAb and our clinical strategy to bring it to patients as quickly as possible.
Thomas Harth, Principal at Ysios Capital stated: “We believe Memo Therapeutics has developed a very powerful antibody that can address the growing concern of BKV infections in kidney transplant recipients.
Alongside AntiBKV, Memo Therapeutics is developing a panel of pre-clinical assets in cancer and viral infections.

Memo Therapeutics increases Series C financing to CHF 45 million

Retrieved on:

화요일, 5월 7, 2024

FDA, Phase, Cancer, Venture round, BK, Kidney, Risk, MTX, BK virus, Viremia, Memo, Disease, Patient, Kidney transplantation, BKV, CHF, Infection, Therapy, Viral, Pharmaceutical industry

Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.

Key Points:

Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
Erik van den Berg, CEO of Memo Therapeutics, commented: “This financing provides further external endorsement of the potential of our highly potent anti-BK virus mAb and our clinical strategy to bring it to patients as quickly as possible.
Thomas Harth, Principal at Ysios Capital stated: “We believe Memo Therapeutics has developed a very powerful antibody that can address the growing concern of BKV infections in kidney transplant recipients.
Alongside AntiBKV, Memo Therapeutics is developing a panel of pre-clinical assets in cancer and viral infections.

BNY Mellon Municipal Income Fund, Inc. (NYSE: DMF) Declares Distribution

Retrieved on:

수요일, 5월 8, 2024

Banking, Professional Services, Finance, BNY Mellon, NAV, BNY Mellon Investment Management, BK, Investment, DMF, Bank, Newsroom, BNY, Fund, Security (finance)

BNY Mellon Investment Management is one of the world’s largest asset managers, with $2.0 trillion in assets under management as of March 31, 2024.

Key Points:

BNY Mellon Investment Management is one of the world’s largest asset managers, with $2.0 trillion in assets under management as of March 31, 2024.
Through a client-first approach, BNY Mellon Investment Management brings investors specialist expertise through its seven investment firms offering solutions across every major asset class and backed by the breadth and scale of BNY Mellon.
BNY Mellon Investment Management is a division of BNY Mellon, which has $48.8 trillion in assets under custody and/or administration as of March 31, 2024.
BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

BNY Mellon Municipal Income Fund, Inc. (NYSE: DMF) Declares Distribution

Retrieved on:

수요일, 5월 8, 2024

Banking, Asset Management, Professional Services, Finance, BNY Mellon, NAV, BNY Mellon Investment Management, BK, Investment, DMF, Bank, Newsroom, Fund, Security (finance)

BNY Mellon Investment Management is one of the world’s largest asset managers, with $2.0 trillion in assets under management as of March 31, 2024.

Key Points:

BNY Mellon Investment Management is one of the world’s largest asset managers, with $2.0 trillion in assets under management as of March 31, 2024.
Through a client-first approach, BNY Mellon Investment Management brings investors specialist expertise through its seven investment firms offering solutions across every major asset class and backed by the breadth and scale of BNY Mellon.
BNY Mellon Investment Management is a division of BNY Mellon, which has $48.8 trillion in assets under custody and/or administration as of March 31, 2024.
BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

Burger King® Celebrates 70 Years With a New Birthday Pie Dessert and a Week Full of Delicious Deals

Retrieved on:

수요일, 5월 8, 2024

Retail, Restaurant, Bar, Other Retail, Food, Beverage, Member, Multimedia, BK, Burger King, Fast food

Burger King ® is inviting Guests to celebrate its milestone birthday with an all new and festive dessert – the Birthday Pie Slice.

Key Points:

Burger King ® is inviting Guests to celebrate its milestone birthday with an all new and festive dessert – the Birthday Pie Slice.
View the full release here: https://www.businesswire.com/news/home/20240508612938/en/
Burger King invites Guests nationwide to celebrate its 70th birthday with an all new sweet treat - Birthday Pie.
The week-long line-up of deals* includes:
Tuesday, May 28: In honor of National Hamburger Day, enjoy a free hamburger with a purchase $0.70 or more.
Celebrate the brand with a free Birthday Pie Slice with a purchase of $0.70 or more.

BNY Mellon's Pershing Announces the Agenda for INSITE 2024

Retrieved on:

월요일, 5월 6, 2024

BNY Mellon, BK, Interview, Social media, BNY Mellon Investment Management, Wove paper, Convention center, Next Level, Bank, Bloomberg, Grand Ole Opry, Cryptocurrency

NEW YORK, May 6, 2024 /PRNewswire/ -- The Bank of New York Mellon Corporation ("BNY Mellon") (NYSE:BK), the global financial services company, has released the lineup for Pershing's INSITE 2024, hosted at the Gaylord Opryland Resort & Convention Center in Nashville, Tennessee, June 4-6. This year's theme is "Next Level," with a focus on how investment firms and advisors can harness technology, data and other innovations to deliver next-level solutions for their clients.

Key Points:

NEW YORK, May 6, 2024 /PRNewswire/ -- The Bank of New York Mellon Corporation ("BNY Mellon") (NYSE:BK), the global financial services company, has released the lineup for Pershing's INSITE 2024 , hosted at the Gaylord Opryland Resort & Convention Center in Nashville, Tennessee, June 4-6.
This year's theme is "Next Level," with a focus on how investment firms and advisors can harness technology, data and other innovations to deliver next-level solutions for their clients.
For more information about INSITE 2024—from speaker bios to the full agenda—visit the INSITE website .
And join the conversation on social media by following @Pershing on LinkedIn and Twitter, and use the #realinsite hashtag.

Intercontinental Exchange, Inc. Commences Private Exchange Offer for Black Knight InfoServ LLC’s Outstanding 3.625% Senior Notes due 2028

Retrieved on:

금요일, 5월 3, 2024

Principal amount of ICE Notes issued in exchange for each $1,000 principal amount of BK Notes validly tendered and accepted for exchange.

Key Points:

Principal amount of ICE Notes issued in exchange for each $1,000 principal amount of BK Notes validly tendered and accepted for exchange.
Exchange Consideration involves the issuance of $970 principal amount of ICE Notes, as opposed to $1,000 principal amount of ICE Notes, for each $1,000 principal amount of BK Notes validly tendered and accepted for exchange.
Settlement of the Exchange Offer is expected to occur on or about June 5, 2024, unless ICE extends the Expiration Date or terminates the Exchange Offer.
The Exchange Offer is not conditioned upon any minimum aggregate principal amount of BK Notes being validly tendered for exchange.

BNY Mellon Municipal Bond Infrastructure Fund, Inc. (NYSE: DMB) Announces Distribution

Retrieved on:

목요일, 5월 2, 2024

Asset Management, Professional Services, Finance, BNY Mellon, NAV, BNY Mellon Investment Management, BK, DMB, Bank, Newsroom, BNY, Policy, Fund, Security (finance)

BNY Mellon Municipal Bond Infrastructure Fund, Inc. (NYSE: DMB) today announced a distribution of $0.0300 per share of common stock, payable on June 3, 2024 to shareholders of record at the close of business on May 17, 2024.

Key Points:

BNY Mellon Municipal Bond Infrastructure Fund, Inc. (NYSE: DMB) today announced a distribution of $0.0300 per share of common stock, payable on June 3, 2024 to shareholders of record at the close of business on May 17, 2024.
BNY Mellon Investment Management is one of the world’s largest asset managers, with $2.0 trillion in assets under management as of March 31, 2024.
Through a client-first approach, BNY Mellon Investment Management brings investors specialist expertise through its seven investment firms offering solutions across every major asset class and backed by the breadth and scale of BNY Mellon.
BNY Mellon Investment Management is a division of BNY Mellon, which has $48.8 trillion in assets under custody and/or administration as of March 31, 2024.

Talisker Intersects 56.88 g/t Au over 1.00 Metre from the Bralorne Gold Project Resource Conversion Program

Retrieved on:

수요일, 4월 17, 2024

Vein, TSK, BK, TSX, Bralorne, Talisker, Road

Talisker initiated resource conversion drilling on October 17, 2023, with 15,000 metres of planned drilling and completed the program on February 15, 2024.

Key Points:

Talisker initiated resource conversion drilling on October 17, 2023, with 15,000 metres of planned drilling and completed the program on February 15, 2024.
Hole SB-2024-018 also intersected 11.74 g/t Au over 2.15 metres within a broader intercept of 3.31 g/t Au over 11.00 metres on the BK-9870 Vein.
Hole SB-2024-007 intersected 8.81 g/t Au over 4.15 metres within a broader intercept of 3.34 g/t Au over 17.75 metres on the BK-9870 Vein.
The resource conversion drill program focused on increasing confidence in the Alhambra, BK and BK-9870 Veins.

Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome

Retrieved on:

월요일, 4월 15, 2024

SPG601 works by restoring synaptic function to address core symptoms of FXS.

Key Points:

SPG601 works by restoring synaptic function to address core symptoms of FXS.
The Phase 2a trial will evaluate the neurophysiological and clinical effects of single-dose SPG601 and placebo in adult men with FXS.
SPG601 is a novel small molecule BK channel activator that works by binding to BK channels and increasing their activation to restore synaptic function.
We look forward to the first study of a BK channel modulator in humans with Fragile X and taking the first step to evaluate this important drug mechanism in Fragile X Syndrome.”